Potential indications: wet macular degeneration, diabetes retinopathy, vascular obstructive macular edema

Description:

1. For the treatment of wet age-related macular degeneration.

2. Bispecific nano antibody, fused with HSA nano antibody. Through the antagonistic effect on the target, it can inhibit the growth of endothelial cells and neovascularization, and achieve a two pronged approach to prevent neovascularization, which has more advantages than VEGF single target inhibitor.

3. Albumin nano antibody can prolong the drug half-life, further prolong the administration time and reduce the administration frequency.